Eli Lilly’s ascent in 2025 is not the outcome of hype, nor is it a temporary … Eli Lilly Surges to Third in 2025 Rankings Fueled by Explosive GLP-1 Demand for Mounjaro and ZepboundRead more
GLP-1
GLP-1 and the Obesity Market: The Sales Playbook Behind Pharma’s New Gold Rush
The world’s largest pharmaceutical companies have found their new gold rush, and it’s not oncology this … GLP-1 and the Obesity Market: The Sales Playbook Behind Pharma’s New Gold RushRead more
GLP-1 Dynamics: Adaptive Sales Tactics in the Evolving Obesity Arena
The landscape of obesity treatments is undergoing a rapid transformation. As advancements in medical science continue, … GLP-1 Dynamics: Adaptive Sales Tactics in the Evolving Obesity ArenaRead more